PDE4A and metabolic dysfunction-associated steatohepatitis: Based on preclinical findings, the novel PDE4 inhibitor ASP9831 was tested in Phase I and Phase II trials for nonalcoholic steatohepatitis (NASH), but failed to improve biochemical biomarkers of the disease (153).